Dr. Bernard Thebaud

Dr. Bernard Thebaud is a clinician-scientist with a focus on the clinical translation of stem cell-based therapies for lung diseases. Dr. Thébaud is a senior scientist with the Ottawa Hospital Research Institute (OHRI) and Children's Hospital of Eastern Ontario Research Institute (CHEO RI), and a neonatologist with the Children's Hospital of Eastern Ontario (CHEO), where he provides care to critically ill newborns. He is a Professor of Pediatrics at the University of Ottawa, Ottawa Partnership Research Chair in Regenerative Medicine and holds a Tier 1 Canada Research Chair in Lung Stem Cell Biology and Regeneration. Thebaud is leading the charge for the AAV therapy, the creator of the AAVENGERS. With him and the help of his team, they will cure our sons and hundreds of thousands of other children.

Dr. Sarah Wootton

Associate Professor – Department of Pathobiology, University of Guelph, Ontario Veterinary College. The overarching goal of research in Dr. Wootton's lab is to engineer viral therapies to prevent, treat or cure illnesses including infectious diseases, cancer, monogenic disorders of the lung. One of her core research areas focuses on adeno-associated virus (AAV) vectors. Working alongside Dr. Thebaud with the plan to cure and treat interstitial lung diseases caused by ABCA3 and other genetic diseases like this.

Dr. Matthias Griese

Professor of Pediatrics, Hauner Children's Hospital, University of Munich, Germany. Dr. Griese is the world's most active physician looking for repurposed medications for these types of rare diseases.

Dr. Larry Nogee

Dr. Lawrence Nogee is a professor of pediatrics at the Johns Hopkins University School of Medicine. His area of clinical expertise is neonatology, with a particular focus on genetic surfactant dysfunction disorders and neonatal lung disease. He is the world-leading expert for these types of genetic diseases.